Condition: Myelodysplastic Syndromes · Refractory Anemia With Excess Blasts · Chronic Myelomonocytic Leukemia · Sponsor: Traws Pharma, Inc.
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Stanford University Cancer Center | Stanford, California, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| University of Chicago Medicine | Chicago, Illinois, United States | — |
| University of Kansas Cancer Center and Medical Pavilion | Westwood, Kansas, United States | — |
| Greenbaum Cancer Center University of Maryland | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Mount Sinai Medical Center | New York, New York, United States | — |
| Columbia University Medical Center | New York, New York, United States | — |
| New York Presbyterian Hospital-Weill Cornell Medical College | New York, New York, United States | — |
| Montefiore Medical Center | The Bronx, New York, United States | — |
| University of Texas Southwestern Medical Center-Parkland Hospital | Dallas, Texas, United States | — |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01928537